WITHDRAWN: From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2- breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• CDK4/6 inhibitors combined with endocrine therapy are initially effective for HR+/HER2- mBC.
• Resistance to these inhibitors is a significant clinical challenge, driven by alterations in cell cycle machinery.
• Mechanisms include Rb dysfunction, cyclin E1 overexpression, and CDK4/6 upregulation, leading to cell cycle progression independent of inhibition.

Purpose of the Study:

• To review emerging cell cycle-centric resistance mechanisms to CDK4/6 inhibitors in HR+/HER2- mBC.
• To highlight innovative therapeutic strategies for overcoming this resistance.
• To discuss the potential of selective CDK2/4 inhibitors and KAT inhibitors.

Main Methods:

• Literature review of recent advances in understanding resistance mechanisms.
• Analysis of emerging therapeutic strategies targeting cell cycle pathways.
• Focus on clinical trial data for novel inhibitors.

Main Results:

• Resistance often involves disruptions in the G1/S checkpoint, such as Rb loss or CDK2/4/6 alterations.
• Selective CDK2/4 inhibitors demonstrate encouraging activity in early trials for resistant tumors.
• KAT inhibition is an emerging approach to modulate signaling and sensitize cells to therapy.

Conclusions:

• Overcoming CDK4/6 inhibitor resistance requires targeting cell cycle pathways and exploring novel agents.
• Selective CDK2/4 inhibition and KAT inhibition represent promising next-generation strategies.
• Further large-scale studies are needed to validate the efficacy of these novel approaches in HR+/HER2- mBC.